An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
NCT02098291
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Pancreatic Cancer
Interventions
DRUG:
G17DT
Sponsor
Cancer Advances Inc.